SynthesisFrontiers in oncology2026
Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bupleurum-containing formulas are widely used in China as adjunct to chemotherapy for triple-negative breast cancer (TNBC). However, systematic evidence on their efficacy and safety remains limited. This study evaluates the clinical effects and safety of Bupleurum-containing formulas combined with chemotherapy in the patients with TNBC. Methods: We searched seven electronic databases (PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), Sinomed, VIP Database, and Wanfang Database) from inception to January 31, 2026. Studies meeting predefined inclusion criteria were identified through a systematic search. Two researchers independently conducted study selection, data extraction, and risk of bias assessment to ensure accuracy and reduce potential bias. Results: Compared with chemotherapy alone, Bupleurum-containing traditional Chinese medicine (TCM) formulas combined with chemotherapy improved several clinical outcomes in patients with TNBC. The combined treatment significantly increased the objective response rate (ORR) (RR = 1.32, 95% CI: 1.18-1.48, Conclusion: Combining Bupleurum-containing TCM formulas with chemotherapy shows potential in improving ORR, DCR, and QOL, while reducing treatment-related toxicity in patients with TNBC. This approach may serve as an adjunctive strategy, but these findings should be interpreted with caution, and further high-quality studies are needed.This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol was prospectively registered in the PROSPERO database (registration number: CRD420251269445). Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251269445.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.